<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01162122</url>
  </required_header>
  <id_info>
    <org_study_id>V70_27</org_study_id>
    <nct_id>NCT01162122</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects</brief_title>
  <official_title>A Phase III, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Safety and Immunogenicity and the Consistency of Three Consecutive Lots of a MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects Aged 65 Years and Older</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The present phase III study aims to evaluate the safety and immunogenicity of MF59-adjuvanted
      subunit seasonal influenza vaccine and to evaluate the consistency in the manufacturing
      process of three consecutive lots of MF59-adjuvanted subunit seasonal influenza vaccine with
      respect to immunogenicity in subjects aged 65 years and older. The active comparator
      non-adjuvanted seasonal influenza vaccine is approved for use in this age group in the United
      States and will be used to provide a comparative assessment for immunogenicity and safety.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Titers in Subjects After Receiving One Dose of Lot 1 or Lot 2 or Lot 3 of aTIV</measure>
    <time_frame>Day 22 post vaccination</time_frame>
    <description>Immunologic equivalence of 3 consecutive production lots of aTIV (Lot 1, Lot 2 and Lot 3), was assessed in terms of Hemagglutination Inhibition (HI) Geometric Mean Titers (GMTs) in subjects, at three weeks after vaccination, against each vaccine strain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of aTIV Versus TIV in Terms of Geometric Mean Titers (GMTs) Against Homologous Strains - PPS</measure>
    <time_frame>Day 22 post vaccination</time_frame>
    <description>The non-inferiority of HI antibody responses of aTIV compared to TIV assessed in terms of post vaccination GMTs at three weeks after vaccination against the three homologous vaccine strains.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of aTIV Versus TIV in Terms of Percentage of Subjects Achieving Seroconversion Against Homologous Strains-PPS</measure>
    <time_frame>Day 22 post vaccination</time_frame>
    <description>The non-inferiority of HI antibody responses of aTIV compared to TIV assessed in terms of percentage of subjects achieving seroconversion at three weeks after vaccination against the three homologous vaccine strains.
Seroconversion defined as prevaccination HI titer &lt;10 and postvaccination HI titer ≥40 or at least a 4-fold increase in HI titers from prevaccination HI titer ≥10.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of aTIV Versus TIV in Terms of GMTs Against Homologous Strains-Full Analysis Set (FAS)</measure>
    <time_frame>Day 22 post vaccination</time_frame>
    <description>The superiority of HI antibody responses of aTIV compared to TIV assessed in terms of post vaccination GMTs at three weeks after vaccination against the three homologous vaccine strains.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of aTIV Versus TIV in Terms of Percentage of Subjects Achieving Seroconversion Against Homologous Strains-FAS</measure>
    <time_frame>Day 22 post vaccination</time_frame>
    <description>The superiority of HI antibody responses of aTIV compared to TIV assessed in terms of percentage of subjects achieving seroconversion at three weeks after vaccination against the three homologous vaccine strains.
Seroconversion defined as prevaccination HI titer &lt;10 and postvaccination HI titer ≥40 or at least a 4-fold increase in HI titers from prevaccination HI titer ≥10.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects With HI Titers ≥40 Against Homologous Strains</measure>
    <time_frame>Day 22 post vaccination</time_frame>
    <description>The percentage of subjects demonstrating HI titers ≥40, in overall group and in subjects with pre-defined co-morbidities (high risk group), against homologous strains, three weeks after vaccination with aTIV or TIV.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects Achieving Seroconversion in HI Titers, Against Homologous Strains</measure>
    <time_frame>Day 22 post vaccination</time_frame>
    <description>The percentage of subjects achieving seroconversion in HI titers from baseline, in overall group and in subjects with pre-defined co-morbidities (high risk group), against homologous strains, three weeks after vaccination with aTIV or TIV.
Seroconversion is defined as prevaccination HI titer &lt;10 and postvaccination HI titer ≥40 or at least a 4-fold increase in HI titers from prevaccination HI titer ≥10.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Ratio (GMR) of Post- Versus Pre-vaccination HI Titers Against Homologous Strains</measure>
    <time_frame>Day 22 post vaccination</time_frame>
    <description>The GMR of post-vaccination versus pre-vaccination HI titers (day 22/day 1) in overall group and in subjects with pre-defined co-morbidities (high risk group), against homologous strains, three weeks after vaccination with aTIV or TIV.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects With HI Titers ≥40 Against Heterologous Strains</measure>
    <time_frame>Day 22 post vaccination</time_frame>
    <description>The percentage of subjects demonstrating HI titers ≥40, in overall group and in subjects with pre-defined co-morbidities (high risk group), against heterologous strains, three weeks after vaccination with aTIV or TIV.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Ratio (GMR) of Post- Versus Pre-vaccination HI Titers, Against Heterologous Strains</measure>
    <time_frame>Day 22 post vaccination</time_frame>
    <description>The GMR of post-vaccination versus pre-vaccination HI titers (day 22/day 1) in overall group and in subjects with pre-defined co-morbidities (high risk group), against heterologous strains, three weeks after vaccination with aTIV or TIV.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects Achieving Seroconversion in HI Titers, Against Heterologous Strains</measure>
    <time_frame>Day 22 post vaccination</time_frame>
    <description>The percentage of subjects achieving seroconversion in HI titers from baseline, in overall group and in subjects with pre-defined co-morbidities (high risk group), against heterologous strains, three weeks after vaccination with aTIV or TIV.
Seroconversion is defined as prevaccination HI titer &lt;10 and postvaccination HI titer ≥40 or at least a 4-fold increase in HI titers from prevaccination HI titer ≥10.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of aTIV Versus TIV in High Risk Group in Terms of GMTs Against Homologous Strains-PPS</measure>
    <time_frame>Day 22 post vaccination</time_frame>
    <description>The non-inferiority of HI antibody responses of ATIV compared to TIV, in subjects with pre-defined co-morbidities (high risk subjects), was assessed in terms of post vaccination GMTs at three weeks after vaccination against the three homologous vaccine strains.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of HI Antibody Responses of aTIV Versus TIV, in High Risk Group in Terms of Percentage of Subjects Achieving Seroconversion Against Homologous Strains-PPS</measure>
    <time_frame>Day 22 post vaccination</time_frame>
    <description>The non-inferiority of HI antibody responses of ATIV compared to TIV, in subjects with pre-defined co-morbidities (high risk group), assessed in terms of percentage of subjects achieving seroconversion at three weeks after vaccination against the homologous vaccine strains.
Seroconversion is defined as prevaccination HI titer &lt;10 and postvaccination HI titer ≥40 or at least a 4-fold increase in HI titers from prevaccination HI titer ≥10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of aTIV Versus TIV in High Risk Group in Terms of GMTs Against Homologous Strains-FAS</measure>
    <time_frame>Day 22 post vaccination</time_frame>
    <description>The superiority of HI antibody responses of aTIV compared to TIV, in subjects with predefined co-morbidities (high risk group) assessed in terms of post vaccination GMTs at three weeks after vaccination against the three homologous vaccine strains.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of HI Antibody Responses of aTIV Versus TIV, in High Risk Group in Terms of Percentage of Subjects Achieving Seroconversion Against Homologous Strains-FAS</measure>
    <time_frame>Day 22 postvaccination</time_frame>
    <description>The superiority of HI antibody responses of aTIV compared to TIV, in subjects with pre-defined co-morbidities (high risk group), assessed in terms of percentage of subjects achieving seroconversion at three weeks after vaccination against the homologous vaccine strains.
Seroconversion is defined as prevaccination HI titer &lt;10 and postvaccination HI titer ≥40 or at least a 4-fold increase in HI titers from prevaccination HI titer ≥10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of aTIV Versus TIV in Terms of GMTs Against Heterologous Strains-PPS</measure>
    <time_frame>Day 22 post vaccination</time_frame>
    <description>The non-inferiority of HI antibody responses of aTIV compared to TIV against the heterologous vaccine strains, in overall group and in subjects with pre-defined co-morbidities (high risk subjects), was assessed in terms of post vaccination GMTs at three weeks after vaccination .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of aTIV Versus TIV in Terms of GMTs Against Heterologous Strains-FAS</measure>
    <time_frame>Day 22 post vaccination</time_frame>
    <description>The superiority of HI antibody responses of aTIV compared to TIV against the heterologous vaccine strains, in overall group and in subjects with pre-defined co-morbidities (high risk subjects), was assessed in terms of post vaccination GMTs at three weeks after vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of HI Antibody Responses of aTIV Versus TIV, in Terms of Percentage of Subjects Achieving Seroconversion Against Heterologous Strains-PPS</measure>
    <time_frame>Day 22 postvaccination</time_frame>
    <description>The non-inferiority of HI antibody responses of aTIV compared to TIV against the heterologous strains, in overall group and in subjects with pre-defined co-morbidities (high risk group), assessed in terms of percentage of subjects achieving seroconversion at three weeks after vaccination.
Seroconversion is defined as prevaccination HI titer &lt;10 and postvaccination HI titer ≥40 or at least a 4-fold increase in HI titers from prevaccination HI titer ≥10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of aTIV Versus TIV in Terms of Percentage of Subjects Achieving Seroconversion Against Heterologous Strains-FAS</measure>
    <time_frame>Day 22 post vaccination</time_frame>
    <description>The superiority of HI antibody responses of aTIV compared to TIV against the heterologous vaccine strains, in overall group and in subjects with pre-defined co-morbidities (high risk subjects), was assessed in terms of percentage of subjects achieving seroconversion, at three weeks after vaccination.
Seroconversion is defined as prevaccination HI titer &lt;10 and postvaccination HI titer ≥40 or at least a 4-fold increase in HI titers from prevaccination HI titer ≥10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistence of GMTs Against Homologous and Heterologous Strains</measure>
    <time_frame>Day 181, Day 366 post vaccination</time_frame>
    <description>The GMTs against homologous and heterologous strains, persisting in subjects at six months (day 181) and one year (day 366) after vaccination with either aTIV or TIV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Seroconversion Upto One Year After Vaccination, Against Homologous and Heterologous Strains</measure>
    <time_frame>Day 181, Day 366 post vaccination</time_frame>
    <description>The percentage of subjects demonstrating seroconversion in HI titers against homologous and heterologous strains, at six months (day 181) and one year (day 366) after vaccination with either aTIV or TIV.
Seroconversion is defined as prevaccination HI titer &lt;10 and postvaccination HI titer ≥40 or at least a 4-fold increase in HI titers from prevaccination HI titer ≥10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Influenza Like Illness (ILI) Across Vaccine Groups</measure>
    <time_frame>Day 22 through Day 366 post vaccination</time_frame>
    <description>The number of subjects reporting ILI from three weeks after vaccination to up to one year in aTIV group compared to TIV group, by country.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of High Risk Subjects With Exacerbation of Preexisting Chronic Disease, Across Vaccine Groups</measure>
    <time_frame>Day 1 through Day 366 post vaccination</time_frame>
    <description>The number of high risk subjects reporting exacerbation of preexisting chronic conditions (i.e.congestive heart failure, Chronic Obstructive Pulmonary disease (COPD), asthma, hepatic disease, renal insufficiency, and neurological/neuromuscular or metabolic disorders including diabetes mellitus) in aTIV group compared to TIV group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Healthcare Utilization Across Vaccine Groups</measure>
    <time_frame>Day 1 through Day 366 post vaccination</time_frame>
    <description>The number of subjects with emergency room visits, unscheduled physician visits, and hospitalizations due to community acquired influenza or pneumonia, cardiopulmonary disease, cardiac disease, respiratory or pulmonary disease,in aTIV group compared to TIV group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cause Mortality Rate, Across Vaccine Groups</measure>
    <time_frame>Day 1 through Day 366 post vaccination</time_frame>
    <description>The all-cause mortality rate (excluding injury)reported in aTIV group compared to TIV group, by country.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Adverse Events Following Vaccination</measure>
    <time_frame>Day 1 through Day 7 post vaccination</time_frame>
    <description>The number of subjects reporting solicited local and systemic adverse events and other adverse events in aTIV group compared to TIV group.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7109</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>aTIV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received one dose of MF59-adjuvanted trivalent subunit influenza vaccine (aTIV) from one of three consecutive lots (Lot 1, Lot 2 or Lot 3).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Licensed TIV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received one dose of non-adjuvanted trivalent subunit influenza vaccine (TIV).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MF59 adjuvanted trivalent subunit influenza vaccine (aTIV)</intervention_name>
    <description>one dose 0.5 mL administered IM in the deltoid muscle of (preferably) the non-dominant arm</description>
    <arm_group_label>aTIV</arm_group_label>
    <other_name>Fluad</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Non-adjuvanted trivalent subunit influenza vaccine (TIV)</intervention_name>
    <description>one 0.5 mL dose administered IM in the deltoid muscle of (preferably) the non-dominant arm</description>
    <arm_group_label>Licensed TIV</arm_group_label>
    <other_name>Agriflu</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Males and females subjects aged ≥65 years at day of vaccination who are willing and able to
        comply to study procedures.

        Exclusion Criteria:

          1. Individuals with behavioral or cognitive impairment or a psychiatric condition or with
             a history of any illness that,in the opinion of the investigator, would have
             interfered with the subject's ability to participate in the study.

          2. Individuals who were not able to comprehend and/or follow all required study
             procedures for the whole period of the study.

          3. Known or suspected impairment/alteration of immune function.

          4. Individuals with a known bleeding diathesis.

          5. History of Guillain-Barré syndrome.

          6. Individuals with history of allergy to vaccine components and/or a history of any
             anaphylaxis, serious vaccine reactions or hypersensitivity to influenza viral
             proteins, egg proteins (including ovalbumin), polymyxin, neomycin, betapropiolactone,
             thimerosal/ sodium ethylmercurothiosalicylate/ mercury and nonylphenolethoxylate/
             nonoxynol-9 (spermicide).

          7. Receipt of another investigational agent within 30 days prior to enrollment in the
             study or before completion of the safety follow-up period in another study.

          8. Individuals who had received any other vaccines within 2 weeks for inactivated
             vaccines or 4 weeks for live vaccines prior to enrollment in this study or who had
             planned to receive any vaccine within 3 weeks from the study vaccine.

          9. Individuals who had received vaccination against seasonal influenza in the previous 6
             months.

         10. Individuals with oral temperature ≥38.0°C (≥100.4°F) on day of study vaccination.

         11. Individuals with history of substance or alcohol abuse within the past 2 years.

         12. Individuals providing consent who did not consent to the retention of their serum
             samples after study completion.

         13. Elective surgery or hospitalization planned to occur during the treatment phase or
             during the follow-up phase that, according to the opinion of the investigator, might
             have poses additional risk to the subject.

         14. Subjects from whom blood could not be drawn at visit 1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>301, Tatum Highlands Medical Associates PLLC, 26224 N Tatum Blvd 15A</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85253</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>318 Avail Clinical Research, 860 Peachwood Drive</name>
      <address>
        <city>Deland</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>306 Westside Center for Clinical Research, 810 Lane Avenue South</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>328 Miami Research Associates, 6141 Sunset Drive</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>320 Johnson County Clin-Trials, 15602 College Blvd</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>316 Heartland Research Associates LLC - Axtell Clinic - PA, 700 Medical Center Dr</name>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>310 Heartland Research Associates LLC, 3730 N Ridge Road Suite 600</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>322 Heartland Research Associates Wichita, 1709 S. Rock Road</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>314 Saint Louis Univ Med Div of Infectious Diseases Immunology, 1100 S Grand Blvd DRC- Rm 827</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>330 Mercy Health Research, 12680 Olive Blvd Suite 200</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>313 Clinical Research Center of Nevada, 7425 W Azure Suite 150</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>311 Regional Clinical Research INC, 415 Hooper Road</name>
      <address>
        <city>Endwell</city>
        <state>New York</state>
        <zip>13760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>326 Triangle Medical Research, 5816 Creedmoor Rd. Suite 104</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>332 Piedmont Medical Research, 1901 S. Hawthorne Rd. Suite 306</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>303 Prestige Clinical Research, 333 Conover Drive</name>
      <address>
        <city>Franklin</city>
        <state>Ohio</state>
        <zip>45005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>325 Omega Medical Research, 400 Bald Hill Road</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>312 Spartanburg Regional Medical Center, 485 Simuel Road</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>321 Jordan River Family Medicine, 1868 West 9800 South Ste 100</name>
      <address>
        <city>Jordan</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>317 J. Lewis Research Inc., 2295 Foothill Drive</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>305 Foothill Family Clinic South, 6360 South 3000 East</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>323 PI Coor Clinical Research LCC, 10721 Main St Suite 1500</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>209, Centro de Investigacion CAFAM</name>
      <address>
        <city>Avenida Carrera 68</city>
        <state>Bogota</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>206, Centro de Atencion e Investigacion Medica CAIMED</name>
      <address>
        <city>Carrera 42A</city>
        <state>Bogota</state>
        <zip>1750</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>213, Centro de Atencion e Investigacion Medica CAIMED</name>
      <address>
        <city>Carrera 42A</city>
        <state>Bogota</state>
        <zip>1750</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>207, Centro de Investigacion Cafesalud Medicina Prepagada</name>
      <address>
        <city>Cra 14 No Piso Sexto</city>
        <state>Bogota</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>203, Health Research International HRI</name>
      <address>
        <city>Clayton ciudad del Saber Edificio 118</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205, Medical and Research Center Calle 53 Urbanizacion Marbella</name>
      <address>
        <city>Consultorios Royal Center 108</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>103, De La Salle Health Sciences Institute</name>
      <address>
        <city>DBB B Dasmarinas</city>
        <state>Cavite</state>
        <zip>4114</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>102, De La Salle Health Sciences Institute</name>
      <address>
        <city>Dbbb Dasmarinas</city>
        <state>Cavite</state>
        <zip>4114</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>105, Manila Doctors Hospital, 667 United Nations Avenue</name>
      <address>
        <city>Ermita</city>
        <state>Manila</state>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>106, Our Lady of Lourdes Hospital, 46 P. Sanchez Street Sta.</name>
      <address>
        <city>Mesa</city>
        <state>Manila</state>
        <zip>1016</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>104 Jose Reyes Memorial Medical Center</name>
      <address>
        <city>Rizal Avenue Avenida Cruz</city>
        <state>Manila</state>
        <zip>1003</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>107 Philippine General Hospital</name>
      <address>
        <city>Taft Avenue</city>
        <state>Manila</state>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>101, Asian Hospital and Medical Center 2205 Civic Drive Filinvest</name>
      <address>
        <city>Corporate City Alabang</city>
        <state>Muntinlupa</state>
        <zip>1781</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>109, Research Institute for Tropical Medicine Department of Health Compound FILINVEST</name>
      <address>
        <city>Corporate City Alabang</city>
        <state>Muntinlupa</state>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>108, City Health Office 1 Rosa City</name>
      <address>
        <city>City Health Office 1</city>
        <state>Rosa City</state>
        <zip>4026</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>110, San Juan de Dios Hospital, 2772 Roxas Blvd</name>
      <address>
        <city>Pasay City</city>
        <zip>1300</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>111, St Lukes Medical Center, 279 E Rodriguez Sr Boulevard</name>
      <address>
        <city>Quezon City</city>
        <zip>1102</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
    <country>Panama</country>
    <country>Philippines</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2010</study_first_submitted>
  <study_first_submitted_qc>July 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2010</study_first_posted>
  <results_first_submitted>January 28, 2014</results_first_submitted>
  <results_first_submitted_qc>June 6, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 12, 2014</results_first_posted>
  <disposition_first_submitted>March 25, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>March 25, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 4, 2011</disposition_first_posted>
  <last_update_submitted>June 16, 2014</last_update_submitted>
  <last_update_submitted_qc>June 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Elderly</keyword>
  <keyword>Influenza</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Safety</keyword>
  <keyword>Adjuvant</keyword>
  <keyword>Adjuvanted</keyword>
  <keyword>Adjuvants</keyword>
  <keyword>Vaccines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>MF59 oil emulsion</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled from 4 sites in Columbia, 2 sites in Panama, 11 sites in Philippines, 21 sites in USA.</recruitment_details>
      <pre_assignment_details>Five enrolled subjects were not randomized and did not receive study vaccination, hence were discontinued.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>aTIV (Pooled)</title>
          <description>Subjects received one dose of MF59-adjuvanted trivalent subunit influenza vaccine (aTIV) from one of three consecutive lots (Lot 1, Lot 2 or Lot 3).</description>
        </group>
        <group group_id="P2">
          <title>Licensed TIV</title>
          <description>Subjects received one dose of non-adjuvanted trivalent subunit influenza vaccine (TIV).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3552"/>
                <participants group_id="P2" count="3552"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated</title>
              <participants_list>
                <participants group_id="P1" count="3541"/>
                <participants group_id="P2" count="3541"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3361"/>
                <participants group_id="P2" count="3356"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="191"/>
                <participants group_id="P2" count="196"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="91"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inappropriate enrollment</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative reason</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to classify</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missing primary reason</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline demography is described for safety set population.
A vaccine different from the vaccine assigned at randomization was administered to 7 subjects in each vaccine group. For the safety analysis, these subjects were reassigned to the vaccine group for the vaccine they actually received.</population>
      <group_list>
        <group group_id="B1">
          <title>aTIV (Pooled)</title>
          <description>Subjects received one dose of MF59-adjuvanted trivalent subunit influenza vaccine (aTIV) from one of three consecutive lots (Lot 1, Lot 2 or Lot 3).</description>
        </group>
        <group group_id="B2">
          <title>Licensed TIV</title>
          <description>Subjects received one dose of non-adjuvanted trivalent subunit influenza vaccine (TIV).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3545"/>
            <count group_id="B2" value="3537"/>
            <count group_id="B3" value="7082"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.0" spread="5.3"/>
                    <measurement group_id="B2" value="71.8" spread="5.3"/>
                    <measurement group_id="B3" value="71.9" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2272"/>
                    <measurement group_id="B2" value="2342"/>
                    <measurement group_id="B3" value="4614"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1273"/>
                    <measurement group_id="B2" value="1195"/>
                    <measurement group_id="B3" value="2468"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers in Subjects After Receiving One Dose of Lot 1 or Lot 2 or Lot 3 of aTIV</title>
        <description>Immunologic equivalence of 3 consecutive production lots of aTIV (Lot 1, Lot 2 and Lot 3), was assessed in terms of Hemagglutination Inhibition (HI) Geometric Mean Titers (GMTs) in subjects, at three weeks after vaccination, against each vaccine strain.</description>
        <time_frame>Day 22 post vaccination</time_frame>
        <population>Analysis was done on the per protocol set population (PPS) i.e all randomised subjects who received the correct vaccine, provided evaluable serum samples, and had no major protocol deviation prior to unblinding.</population>
        <group_list>
          <group group_id="O1">
            <title>aTIV_Lot 1</title>
            <description>Subjects received one dose of MF59-adjuvanted trivalent subunit influenza vaccine (aTIV) from Lot 1</description>
          </group>
          <group group_id="O2">
            <title>aTIV_Lot 2</title>
            <description>Subjects received one dose of MF59-adjuvanted trivalent subunit influenza vaccine (aTIV) from Lot 2</description>
          </group>
          <group group_id="O3">
            <title>aTIV_Lot 3</title>
            <description>Subjects received one dose of MF59-adjuvanted trivalent subunit influenza vaccine (aTIV) from Lot 3</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers in Subjects After Receiving One Dose of Lot 1 or Lot 2 or Lot 3 of aTIV</title>
          <description>Immunologic equivalence of 3 consecutive production lots of aTIV (Lot 1, Lot 2 and Lot 3), was assessed in terms of Hemagglutination Inhibition (HI) Geometric Mean Titers (GMTs) in subjects, at three weeks after vaccination, against each vaccine strain.</description>
          <population>Analysis was done on the per protocol set population (PPS) i.e all randomised subjects who received the correct vaccine, provided evaluable serum samples, and had no major protocol deviation prior to unblinding.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1073"/>
                <count group_id="O2" value="1078"/>
                <count group_id="O3" value="1076"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 strain (N=1072,1078,1075)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="209" lower_limit="189" upper_limit="231"/>
                    <measurement group_id="O2" value="187" lower_limit="170" upper_limit="207"/>
                    <measurement group_id="O3" value="199" lower_limit="180" upper_limit="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 strain (N=1072,1078,1075)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="548" lower_limit="502" upper_limit="598"/>
                    <measurement group_id="O2" value="542" lower_limit="498" upper_limit="591"/>
                    <measurement group_id="O3" value="556" lower_limit="510" upper_limit="606"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56" lower_limit="51" upper_limit="61"/>
                    <measurement group_id="O2" value="56" lower_limit="51" upper_limit="61"/>
                    <measurement group_id="O3" value="58" lower_limit="53" upper_limit="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 95% CIs of GMT ratios for the pairwise lot-to-lot group comparisons should fall within the equivalence range of 0.67 to 1.5.</non_inferiority_desc>
            <param_type>GMT ratio (H1N1 strain)</param_type>
            <param_value>1.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1</ci_lower_limit>
            <ci_upper_limit>1.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 95% CIs of GMT ratios for the pairwise lot-to-lot group comparisons should fall within the equivalence range of 0.67 to 1.5.</non_inferiority_desc>
            <param_type>GMT ratio (H1N1 strain)</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 95% CIs of GMT ratios for the pairwise lot-to-lot group comparisons should fall within the equivalence range of 0.67 to 1.5.</non_inferiority_desc>
            <param_type>GMT ratio (H1N1 strain)</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 95% CIs of GMT ratios for the pairwise lot-to-lot group comparisons should fall within the equivalence range of 0.67 to 1.5.</non_inferiority_desc>
            <param_type>GMT ratio (H3N2 strain)</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 95% CIs of GMT ratios for the pairwise lot-to-lot group comparisons should fall within the equivalence range of 0.67 to 1.5.</non_inferiority_desc>
            <param_type>GMT ratio (H3N2 strain)</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 95% CIs of GMT ratios for the pairwise lot-to-lot group comparisons should fall within the equivalence range of 0.67 to 1.5.</non_inferiority_desc>
            <param_type>GMT ratio (H3N2 strain)</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 95% CIs of GMT ratios for the pairwise lot-to-lot group comparisons should fall within the equivalence range of 0.67 to 1.5.</non_inferiority_desc>
            <param_type>GMT ratio (B strain)</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 95% CIs of GMT ratios for the pairwise lot-to-lot group comparisons should fall within the equivalence range of 0.67 to 1.5.</non_inferiority_desc>
            <param_type>GMT ratio (B strain)</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 95% CIs of GMT ratios for the pairwise lot-to-lot group comparisons should fall within the equivalence range of 0.67 to 1.5.</non_inferiority_desc>
            <param_type>GMT ratio (B strain)</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Comparison of aTIV Versus TIV in Terms of Geometric Mean Titers (GMTs) Against Homologous Strains - PPS</title>
        <description>The non-inferiority of HI antibody responses of aTIV compared to TIV assessed in terms of post vaccination GMTs at three weeks after vaccination against the three homologous vaccine strains.</description>
        <time_frame>Day 22 post vaccination</time_frame>
        <population>Analysis was done on PPS.</population>
        <group_list>
          <group group_id="O1">
            <title>aTIV (Pooled)</title>
            <description>Subjects received one dose of MF59-adjuvanted trivalent subunit influenza vaccine (aTIV) from one of three consecutive lots (Lot 1, Lot 2 or Lot 3).</description>
          </group>
          <group group_id="O2">
            <title>Licensed TIV</title>
            <description>Subjects received one dose of non-adjuvanted trivalent subunit influenza vaccine (TIV).</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of aTIV Versus TIV in Terms of Geometric Mean Titers (GMTs) Against Homologous Strains - PPS</title>
          <description>The non-inferiority of HI antibody responses of aTIV compared to TIV assessed in terms of post vaccination GMTs at three weeks after vaccination against the three homologous vaccine strains.</description>
          <population>Analysis was done on PPS.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3227"/>
                <count group_id="O2" value="3259"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 strain (N=3225,3257)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198" lower_limit="185" upper_limit="211"/>
                    <measurement group_id="O2" value="141" lower_limit="132" upper_limit="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 strain (N=3225,3256)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="544" lower_limit="513" upper_limit="575"/>
                    <measurement group_id="O2" value="337" lower_limit="319" upper_limit="357"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55" lower_limit="52" upper_limit="58"/>
                    <measurement group_id="O2" value="48" lower_limit="46" upper_limit="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of the 95% CI for the day 22 vaccine group GMT ratios for all 3 homologous strains was &gt;0.67.</non_inferiority_desc>
            <param_type>GMT ratio (H1N1 strain)</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.32</ci_lower_limit>
            <ci_upper_limit>1.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of the 95% CI for the day 22 vaccine group GMT ratios for all 3 homologous strains was &gt;0.67.</non_inferiority_desc>
            <param_type>GMT ratio (H3N2 strain)</param_type>
            <param_value>1.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.52</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of the 95% CI for the day 22 vaccine group GMT ratios for all 3 homologous strains was &gt;0.67.</non_inferiority_desc>
            <param_type>GMT ratio (B strain)</param_type>
            <param_value>1.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.08</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Comparison of aTIV Versus TIV in Terms of Percentage of Subjects Achieving Seroconversion Against Homologous Strains-PPS</title>
        <description>The non-inferiority of HI antibody responses of aTIV compared to TIV assessed in terms of percentage of subjects achieving seroconversion at three weeks after vaccination against the three homologous vaccine strains.
Seroconversion defined as prevaccination HI titer &lt;10 and postvaccination HI titer ≥40 or at least a 4-fold increase in HI titers from prevaccination HI titer ≥10.</description>
        <time_frame>Day 22 post vaccination</time_frame>
        <population>Analysis was done on PPS.</population>
        <group_list>
          <group group_id="O1">
            <title>aTIV (Pooled)</title>
            <description>Subjects received one dose of MF59-adjuvanted trivalent subunit influenza vaccine (aTIV) from one of three consecutive lots (Lot 1, Lot 2 or Lot 3).</description>
          </group>
          <group group_id="O2">
            <title>Licensed TIV</title>
            <description>Subjects received one dose of non-adjuvanted trivalent subunit influenza vaccine (TIV).</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of aTIV Versus TIV in Terms of Percentage of Subjects Achieving Seroconversion Against Homologous Strains-PPS</title>
          <description>The non-inferiority of HI antibody responses of aTIV compared to TIV assessed in terms of percentage of subjects achieving seroconversion at three weeks after vaccination against the three homologous vaccine strains.
Seroconversion defined as prevaccination HI titer &lt;10 and postvaccination HI titer ≥40 or at least a 4-fold increase in HI titers from prevaccination HI titer ≥10.</description>
          <population>Analysis was done on PPS.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3227"/>
                <count group_id="O2" value="3259"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 strain (N=3225,3257)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.4" lower_limit="75.9" upper_limit="78.9"/>
                    <measurement group_id="O2" value="67.6" lower_limit="65.9" upper_limit="69.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 strain (N=3225,3256)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.0" lower_limit="72.4" upper_limit="75.5"/>
                    <measurement group_id="O2" value="60.7" lower_limit="59.0" upper_limit="62.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.0" lower_limit="45.2" upper_limit="48.7"/>
                    <measurement group_id="O2" value="41.2" lower_limit="39.5" upper_limit="43.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of the 95% CI for the day 22 differences in seroconversion rates for all 3 homologous strains was ≥-10%.</non_inferiority_desc>
            <param_type>Group difference (H1N1 strain)</param_type>
            <param_value>9.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.1</ci_lower_limit>
            <ci_upper_limit>11.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of the 95% CI for the day 22 differences in seroconversion rates for all 3 homologous strains was ≥-10%.</non_inferiority_desc>
            <param_type>Group difference (H3N2 strain)</param_type>
            <param_value>12.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.5</ci_lower_limit>
            <ci_upper_limit>14.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of the 95% CI for the day 22 differences in seroconversion rates for all 3 homologous strains was ≥-10%.</non_inferiority_desc>
            <param_type>Group difference (B strain)</param_type>
            <param_value>5.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.0</ci_lower_limit>
            <ci_upper_limit>7.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Comparison of aTIV Versus TIV in Terms of GMTs Against Homologous Strains-Full Analysis Set (FAS)</title>
        <description>The superiority of HI antibody responses of aTIV compared to TIV assessed in terms of post vaccination GMTs at three weeks after vaccination against the three homologous vaccine strains.</description>
        <time_frame>Day 22 post vaccination</time_frame>
        <population>Analysis was done on FAS i.e all randomized subjects who received a study vaccination and provided evaluable serum samples both at day 1 and at day 22</population>
        <group_list>
          <group group_id="O1">
            <title>aTIV (Pooled)</title>
            <description>Subjects received one dose of MF59-adjuvanted trivalent subunit influenza vaccine (aTIV) from one of three consecutive lots (Lot 1, Lot 2 or Lot 3).</description>
          </group>
          <group group_id="O2">
            <title>Licensed TIV</title>
            <description>Subjects received one dose of non-adjuvanted trivalent subunit influenza vaccine (TIV).</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of aTIV Versus TIV in Terms of GMTs Against Homologous Strains-Full Analysis Set (FAS)</title>
          <description>The superiority of HI antibody responses of aTIV compared to TIV assessed in terms of post vaccination GMTs at three weeks after vaccination against the three homologous vaccine strains.</description>
          <population>Analysis was done on FAS i.e all randomized subjects who received a study vaccination and provided evaluable serum samples both at day 1 and at day 22</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3479"/>
                <count group_id="O2" value="3482"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 strain (N=3477,3480)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196" lower_limit="184" upper_limit="208"/>
                    <measurement group_id="O2" value="142" lower_limit="134" upper_limit="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 strain (N=3477,3479)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="534" lower_limit="506" upper_limit="563"/>
                    <measurement group_id="O2" value="334" lower_limit="317" upper_limit="353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54" lower_limit="51" upper_limit="57"/>
                    <measurement group_id="O2" value="48" lower_limit="45" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority was established if the lower bound of the 95% CI for the day 22 vaccine group GMT ratios for at least 2 homologous strains was &gt;1.5.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT ratio (H1N1 strain)</param_type>
            <param_value>1.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.29</ci_lower_limit>
            <ci_upper_limit>1.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority was established if the lower bound of the 95% CI for the day 22 vaccine group GMT ratios for at least 2 homologous strains was &gt;1.5.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT ratio (H3N2 strain)</param_type>
            <param_value>1.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.51</ci_lower_limit>
            <ci_upper_limit>1.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority was established if the lower bound of the 95% CI for the day 22 vaccine group GMT ratios for at least 2 homologous strains was &gt;1.5.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT ratio (B strain)</param_type>
            <param_value>1.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.08</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Comparison of aTIV Versus TIV in Terms of Percentage of Subjects Achieving Seroconversion Against Homologous Strains-FAS</title>
        <description>The superiority of HI antibody responses of aTIV compared to TIV assessed in terms of percentage of subjects achieving seroconversion at three weeks after vaccination against the three homologous vaccine strains.
Seroconversion defined as prevaccination HI titer &lt;10 and postvaccination HI titer ≥40 or at least a 4-fold increase in HI titers from prevaccination HI titer ≥10.</description>
        <time_frame>Day 22 post vaccination</time_frame>
        <population>Analysis was done on FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>aTIV (Pooled)</title>
            <description>Subjects received one dose of MF59-adjuvanted trivalent subunit influenza vaccine (aTIV) from one of three consecutive lots (Lot 1, Lot 2 or Lot 3).</description>
          </group>
          <group group_id="O2">
            <title>Licensed TIV</title>
            <description>Subjects received one dose of non-adjuvanted trivalent subunit influenza vaccine (TIV).</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of aTIV Versus TIV in Terms of Percentage of Subjects Achieving Seroconversion Against Homologous Strains-FAS</title>
          <description>The superiority of HI antibody responses of aTIV compared to TIV assessed in terms of percentage of subjects achieving seroconversion at three weeks after vaccination against the three homologous vaccine strains.
Seroconversion defined as prevaccination HI titer &lt;10 and postvaccination HI titer ≥40 or at least a 4-fold increase in HI titers from prevaccination HI titer ≥10.</description>
          <population>Analysis was done on FAS.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3479"/>
                <count group_id="O2" value="3482"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 strain (N=3477, 3480)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.3" lower_limit="75.8" upper_limit="78.6"/>
                    <measurement group_id="O2" value="67.8" lower_limit="66.2" upper_limit="69.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 strain (N=3477,3479)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.7" lower_limit="72.2" upper_limit="75.1"/>
                    <measurement group_id="O2" value="60.6" lower_limit="59.0" upper_limit="62.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.9" lower_limit="45.3" upper_limit="48.6"/>
                    <measurement group_id="O2" value="41.5" lower_limit="39.8" upper_limit="43.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority was established if the lower bound of the 95% CI for the day 22 differences in seroconversion rates for at least 2 homologous strains was &gt;10%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Group difference (H1N1 strain)</param_type>
            <param_value>8.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.9</ci_lower_limit>
            <ci_upper_limit>10.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority was established if the lower bound of the 95% CI for the day 22 differences in seroconversion rates for at least 2 homologous strains was &gt;10%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Group difference (H3N2 strain)</param_type>
            <param_value>12.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.6</ci_lower_limit>
            <ci_upper_limit>14.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority was established if the lower bound of the 95% CI for the day 22 differences in seroconversion rates for at least 2 homologous strains was &gt;10%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Group difference (B strain)</param_type>
            <param_value>5.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.9</ci_lower_limit>
            <ci_upper_limit>7.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With HI Titers ≥40 Against Homologous Strains</title>
        <description>The percentage of subjects demonstrating HI titers ≥40, in overall group and in subjects with pre-defined co-morbidities (high risk group), against homologous strains, three weeks after vaccination with aTIV or TIV.</description>
        <time_frame>Day 22 post vaccination</time_frame>
        <population>Analysis was done on the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>aTIV (Pooled)</title>
            <description>Subjects received one dose of MF59-adjuvanted trivalent subunit influenza vaccine (aTIV) from one of three consecutive lots (Lot 1, Lot 2 or Lot 3).</description>
          </group>
          <group group_id="O2">
            <title>Licensed TIV</title>
            <description>Subjects received one dose of non-adjuvanted trivalent subunit influenza vaccine (TIV).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With HI Titers ≥40 Against Homologous Strains</title>
          <description>The percentage of subjects demonstrating HI titers ≥40, in overall group and in subjects with pre-defined co-morbidities (high risk group), against homologous strains, three weeks after vaccination with aTIV or TIV.</description>
          <population>Analysis was done on the FAS.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3479"/>
                <count group_id="O2" value="3482"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 strain (N=3477,3480) overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.1" lower_limit="90.1" upper_limit="92.0"/>
                    <measurement group_id="O2" value="84.5" lower_limit="83.3" upper_limit="85.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 strain (N=3477,3479) overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.0" lower_limit="98.6" upper_limit="99.3"/>
                    <measurement group_id="O2" value="97.0" lower_limit="96.4" upper_limit="97.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain, overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.6" lower_limit="62.9" upper_limit="66.2"/>
                    <measurement group_id="O2" value="58.9" lower_limit="57.3" upper_limit="60.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1 strain (N=1299,1273), high risk group</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.9" lower_limit="90.3" upper_limit="93.3"/>
                    <measurement group_id="O2" value="85.8" lower_limit="83.7" upper_limit="87.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 strain (N=1299,1273), high risk group</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.7" lower_limit="97.9" upper_limit="99.2"/>
                    <measurement group_id="O2" value="96.7" lower_limit="95.6" upper_limit="97.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain (N=1300,1273), high risk group</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.3" lower_limit="63.7" upper_limit="68.9"/>
                    <measurement group_id="O2" value="61.4" lower_limit="58.7" upper_limit="64.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Achieving Seroconversion in HI Titers, Against Homologous Strains</title>
        <description>The percentage of subjects achieving seroconversion in HI titers from baseline, in overall group and in subjects with pre-defined co-morbidities (high risk group), against homologous strains, three weeks after vaccination with aTIV or TIV.
Seroconversion is defined as prevaccination HI titer &lt;10 and postvaccination HI titer ≥40 or at least a 4-fold increase in HI titers from prevaccination HI titer ≥10.</description>
        <time_frame>Day 22 post vaccination</time_frame>
        <population>Analysis was done on the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>aTIV (Pooled)</title>
            <description>Subjects received one dose of MF59-adjuvanted trivalent subunit influenza vaccine (aTIV) from one of three consecutive lots (Lot 1, Lot 2 or Lot 3).</description>
          </group>
          <group group_id="O2">
            <title>Licensed TIV</title>
            <description>Subjects received one dose of non-adjuvanted trivalent subunit influenza vaccine (TIV).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Achieving Seroconversion in HI Titers, Against Homologous Strains</title>
          <description>The percentage of subjects achieving seroconversion in HI titers from baseline, in overall group and in subjects with pre-defined co-morbidities (high risk group), against homologous strains, three weeks after vaccination with aTIV or TIV.
Seroconversion is defined as prevaccination HI titer &lt;10 and postvaccination HI titer ≥40 or at least a 4-fold increase in HI titers from prevaccination HI titer ≥10.</description>
          <population>Analysis was done on the FAS.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3479"/>
                <count group_id="O2" value="3482"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 strain ( N= 3477,3480), overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.3" lower_limit="75.8" upper_limit="78.6"/>
                    <measurement group_id="O2" value="67.8" lower_limit="66.2" upper_limit="69.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 strain ( N= 3477,3479), overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.7" lower_limit="72.2" upper_limit="75.1"/>
                    <measurement group_id="O2" value="60.6" lower_limit="59.0" upper_limit="62.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain, overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.9" lower_limit="45.3" upper_limit="48.6"/>
                    <measurement group_id="O2" value="41.5" lower_limit="39.8" upper_limit="43.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1 strain ( N= 1299,1273), high risk group</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.6" lower_limit="70.1" upper_limit="75.0"/>
                    <measurement group_id="O2" value="62.0" lower_limit="59.3" upper_limit="64.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 strain ( N= 1299,1273), high risk group</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.9" lower_limit="66.3" upper_limit="71.4"/>
                    <measurement group_id="O2" value="55.2" lower_limit="52.4" upper_limit="58.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain (N= 1299,1273), high risk group</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0" lower_limit="37.3" upper_limit="42.7"/>
                    <measurement group_id="O2" value="34.3" lower_limit="31.6" upper_limit="36.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Ratio (GMR) of Post- Versus Pre-vaccination HI Titers Against Homologous Strains</title>
        <description>The GMR of post-vaccination versus pre-vaccination HI titers (day 22/day 1) in overall group and in subjects with pre-defined co-morbidities (high risk group), against homologous strains, three weeks after vaccination with aTIV or TIV.</description>
        <time_frame>Day 22 post vaccination</time_frame>
        <population>Analysis was done on the FAS</population>
        <group_list>
          <group group_id="O1">
            <title>aTIV (Pooled)</title>
            <description>Subjects received one dose of MF59-adjuvanted trivalent subunit influenza vaccine (aTIV) from one of three consecutive lots (Lot 1, Lot 2 or Lot 3).</description>
          </group>
          <group group_id="O2">
            <title>Licensed TIV</title>
            <description>Subjects received one dose of non-adjuvanted trivalent subunit influenza vaccine (TIV).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Ratio (GMR) of Post- Versus Pre-vaccination HI Titers Against Homologous Strains</title>
          <description>The GMR of post-vaccination versus pre-vaccination HI titers (day 22/day 1) in overall group and in subjects with pre-defined co-morbidities (high risk group), against homologous strains, three weeks after vaccination with aTIV or TIV.</description>
          <population>Analysis was done on the FAS</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3479"/>
                <count group_id="O2" value="3482"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 strain (N=3477, 3480), overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="13" upper_limit="14"/>
                    <measurement group_id="O2" value="9.77" lower_limit="9.14" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 strain (N=3477, 3479), overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="9.48" upper_limit="11"/>
                    <measurement group_id="O2" value="6.54" lower_limit="6.06" upper_limit="7.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain , overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.85" lower_limit="4.59" upper_limit="5.13"/>
                    <measurement group_id="O2" value="4.27" lower_limit="4.04" upper_limit="4.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1 strain (N=1299, 1273), high risk group</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="11" upper_limit="14"/>
                    <measurement group_id="O2" value="9.17" lower_limit="8.28" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 strain (N=1299, 1273), high risk group</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.26" lower_limit="8.31" upper_limit="10"/>
                    <measurement group_id="O2" value="6.24" lower_limit="5.59" upper_limit="6.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain (N=1300, 1273), high risk group</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.48" lower_limit="4.14" upper_limit="4.84"/>
                    <measurement group_id="O2" value="3.99" lower_limit="3.68" upper_limit="4.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of aTIV Versus TIV in High Risk Group in Terms of GMTs Against Homologous Strains-PPS</title>
        <description>The non-inferiority of HI antibody responses of ATIV compared to TIV, in subjects with pre-defined co-morbidities (high risk subjects), was assessed in terms of post vaccination GMTs at three weeks after vaccination against the three homologous vaccine strains.</description>
        <time_frame>Day 22 post vaccination</time_frame>
        <population>Analysis was done on PPS.</population>
        <group_list>
          <group group_id="O1">
            <title>aTIV (Pooled)</title>
            <description>Subjects received one dose of MF59-adjuvanted trivalent subunit influenza vaccine (aTIV) from one of three consecutive lots (Lot 1, Lot 2 or Lot 3).</description>
          </group>
          <group group_id="O2">
            <title>Licensed TIV</title>
            <description>Subjects received one dose of non-adjuvanted trivalent subunit influenza vaccine (TIV).</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of aTIV Versus TIV in High Risk Group in Terms of GMTs Against Homologous Strains-PPS</title>
          <description>The non-inferiority of HI antibody responses of ATIV compared to TIV, in subjects with pre-defined co-morbidities (high risk subjects), was assessed in terms of post vaccination GMTs at three weeks after vaccination against the three homologous vaccine strains.</description>
          <population>Analysis was done on PPS.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1195"/>
                <count group_id="O2" value="1190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 strain (1194, 1190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="221" lower_limit="201" upper_limit="243"/>
                    <measurement group_id="O2" value="161" lower_limit="146" upper_limit="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 strain (1194, 1190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="519" lower_limit="477" upper_limit="565"/>
                    <measurement group_id="O2" value="331" lower_limit="304" upper_limit="360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61" lower_limit="56" upper_limit="66"/>
                    <measurement group_id="O2" value="54" lower_limit="50" upper_limit="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of the 95% CI for the day 22 vaccine group GMT ratios for all 3 homologous strains was &gt;0.67.</non_inferiority_desc>
            <param_type>GMT ratio (H1N1 strain)</param_type>
            <param_value>1.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.25</ci_lower_limit>
            <ci_upper_limit>1.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of the 95% CI for the day 22 vaccine group GMT ratios for all 3 homologous strains was &gt;0.67.</non_inferiority_desc>
            <param_type>GMT ratio (H3N2 strain)</param_type>
            <param_value>1.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.44</ci_lower_limit>
            <ci_upper_limit>1.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of the 95% CI for the day 22 vaccine group GMT ratios for all 3 homologous strains was &gt;0.67.</non_inferiority_desc>
            <param_type>GMT ratio (B strain)</param_type>
            <param_value>1.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.03</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of HI Antibody Responses of aTIV Versus TIV, in High Risk Group in Terms of Percentage of Subjects Achieving Seroconversion Against Homologous Strains-PPS</title>
        <description>The non-inferiority of HI antibody responses of ATIV compared to TIV, in subjects with pre-defined co-morbidities (high risk group), assessed in terms of percentage of subjects achieving seroconversion at three weeks after vaccination against the homologous vaccine strains.
Seroconversion is defined as prevaccination HI titer &lt;10 and postvaccination HI titer ≥40 or at least a 4-fold increase in HI titers from prevaccination HI titer ≥10.</description>
        <time_frame>Day 22 post vaccination</time_frame>
        <population>Analysis was done on PPS.</population>
        <group_list>
          <group group_id="O1">
            <title>aTIV (Pooled)</title>
            <description>Subjects received one dose of MF59-adjuvanted trivalent subunit influenza vaccine (aTIV) from one of three consecutive lots (Lot 1, Lot 2 or Lot 3).</description>
          </group>
          <group group_id="O2">
            <title>Licensed TIV</title>
            <description>Subjects received one dose of non-adjuvanted trivalent subunit influenza vaccine (TIV).</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of HI Antibody Responses of aTIV Versus TIV, in High Risk Group in Terms of Percentage of Subjects Achieving Seroconversion Against Homologous Strains-PPS</title>
          <description>The non-inferiority of HI antibody responses of ATIV compared to TIV, in subjects with pre-defined co-morbidities (high risk group), assessed in terms of percentage of subjects achieving seroconversion at three weeks after vaccination against the homologous vaccine strains.
Seroconversion is defined as prevaccination HI titer &lt;10 and postvaccination HI titer ≥40 or at least a 4-fold increase in HI titers from prevaccination HI titer ≥10.</description>
          <population>Analysis was done on PPS.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1195"/>
                <count group_id="O2" value="1190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 strain (N=1194, 1190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.6" lower_limit="71.0" upper_limit="76.1"/>
                    <measurement group_id="O2" value="61.7" lower_limit="58.9" upper_limit="64.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 strain (N=1194, 1190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.1" lower_limit="66.4" upper_limit="71.7"/>
                    <measurement group_id="O2" value="54.8" lower_limit="51.9" upper_limit="57.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0" lower_limit="37.2" upper_limit="42.8"/>
                    <measurement group_id="O2" value="34.0" lower_limit="31.3" upper_limit="36.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of the 95% CI for the day 22 differences in seroconversion rates for all 3 homologous strains was ≥-10%</non_inferiority_desc>
            <param_type>Group difference (H1N1 strain)</param_type>
            <param_value>11.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.5</ci_lower_limit>
            <ci_upper_limit>14.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of the 95% CI for the day 22 differences in seroconversion rates for all 3 homologous strains was ≥-10%</non_inferiority_desc>
            <param_type>Group difference (H3N2 strain)</param_type>
            <param_value>13.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.8</ci_lower_limit>
            <ci_upper_limit>17.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of the 95% CI for the day 22 differences in seroconversion rates for all 3 homologous strains was ≥-10%</non_inferiority_desc>
            <param_type>Group difference (B strain)</param_type>
            <param_value>5.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.4</ci_lower_limit>
            <ci_upper_limit>8.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of aTIV Versus TIV in High Risk Group in Terms of GMTs Against Homologous Strains-FAS</title>
        <description>The superiority of HI antibody responses of aTIV compared to TIV, in subjects with predefined co-morbidities (high risk group) assessed in terms of post vaccination GMTs at three weeks after vaccination against the three homologous vaccine strains.</description>
        <time_frame>Day 22 post vaccination</time_frame>
        <population>Analysis was done on FAS population.</population>
        <group_list>
          <group group_id="O1">
            <title>aTIV (Pooled)</title>
            <description>Subjects received one dose of MF59-adjuvanted trivalent subunit influenza vaccine (aTIV) from one of three consecutive lots (Lot 1, Lot 2 or Lot 3).</description>
          </group>
          <group group_id="O2">
            <title>Licensed TIV</title>
            <description>Subjects received one dose of non-adjuvanted trivalent subunit influenza vaccine (TIV).</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of aTIV Versus TIV in High Risk Group in Terms of GMTs Against Homologous Strains-FAS</title>
          <description>The superiority of HI antibody responses of aTIV compared to TIV, in subjects with predefined co-morbidities (high risk group) assessed in terms of post vaccination GMTs at three weeks after vaccination against the three homologous vaccine strains.</description>
          <population>Analysis was done on FAS population.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1300"/>
                <count group_id="O2" value="1273"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 strain (N=1299,1273)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="212" lower_limit="194" upper_limit="232"/>
                    <measurement group_id="O2" value="160" lower_limit="147" upper_limit="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 strain (N=1299,1273)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="499" lower_limit="460" upper_limit="540"/>
                    <measurement group_id="O2" value="324" lower_limit="299" upper_limit="351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" lower_limit="55" upper_limit="64"/>
                    <measurement group_id="O2" value="54" lower_limit="50" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority was established if the lower bound of the 95% CI for the day 22 vaccine group GMT ratios for at least 2 homologous strains was &gt;1.5.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT ratio (H1N1 strain)</param_type>
            <param_value>1.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.2</ci_lower_limit>
            <ci_upper_limit>1.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority was established if the lower bound of the 95% CI for the day 22 vaccine group GMT ratios for at least 2 homologous strains was &gt;1.5.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT ratio (H3N2 strain)</param_type>
            <param_value>1.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.42</ci_lower_limit>
            <ci_upper_limit>1.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority was established if the lower bound of the 95% CI for the day 22 vaccine group GMT ratios for at least 2 homologous strains was &gt;1.5.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT ratio (B strain)</param_type>
            <param_value>1.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.03</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With HI Titers ≥40 Against Heterologous Strains</title>
        <description>The percentage of subjects demonstrating HI titers ≥40, in overall group and in subjects with pre-defined co-morbidities (high risk group), against heterologous strains, three weeks after vaccination with aTIV or TIV.</description>
        <time_frame>Day 22 post vaccination</time_frame>
        <population>Analysis was done on the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>aTIV (Pooled)</title>
            <description>Subjects received one dose of MF59-adjuvanted trivalent subunit influenza vaccine (aTIV) from one of three consecutive lots (Lot 1, Lot 2 or Lot 3).</description>
          </group>
          <group group_id="O2">
            <title>Licensed TIV</title>
            <description>Subjects received one dose of non-adjuvanted trivalent subunit influenza vaccine (TIV).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With HI Titers ≥40 Against Heterologous Strains</title>
          <description>The percentage of subjects demonstrating HI titers ≥40, in overall group and in subjects with pre-defined co-morbidities (high risk group), against heterologous strains, three weeks after vaccination with aTIV or TIV.</description>
          <population>Analysis was done on the FAS.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="887"/>
                <count group_id="O2" value="881"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H3N2/Brisbane strain(N=887,880), overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.8" lower_limit="94.3" upper_limit="97.1"/>
                    <measurement group_id="O2" value="94.0" lower_limit="92.2" upper_limit="95.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2/Wisconsin strain, overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.6" lower_limit="98.9" upper_limit="99.9"/>
                    <measurement group_id="O2" value="98.4" lower_limit="97.4" upper_limit="99.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain (N=887,880), overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.2" lower_limit="73.3" upper_limit="79.0"/>
                    <measurement group_id="O2" value="72.4" lower_limit="69.3" upper_limit="75.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2/Brisbane (N=330, 333), high risk group</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.9" lower_limit="91.9" upper_limit="97.0"/>
                    <measurement group_id="O2" value="94.0" lower_limit="90.9" upper_limit="96.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2/Wisconsin (N=330, 333), high risk group</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.7" lower_limit="98.3" upper_limit="100"/>
                    <measurement group_id="O2" value="98.5" lower_limit="96.5" upper_limit="99.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain (N=330, 333), high risk group</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3" lower_limit="78.9" upper_limit="87.2"/>
                    <measurement group_id="O2" value="78.4" lower_limit="73.6" upper_limit="82.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Ratio (GMR) of Post- Versus Pre-vaccination HI Titers, Against Heterologous Strains</title>
        <description>The GMR of post-vaccination versus pre-vaccination HI titers (day 22/day 1) in overall group and in subjects with pre-defined co-morbidities (high risk group), against heterologous strains, three weeks after vaccination with aTIV or TIV.</description>
        <time_frame>Day 22 post vaccination</time_frame>
        <population>Analysis was done on the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>aTIV (Pooled)</title>
            <description>Subjects received one dose of MF59-adjuvanted trivalent subunit influenza vaccine (aTIV) from one of three consecutive lots (Lot 1, Lot 2 or Lot 3).</description>
          </group>
          <group group_id="O2">
            <title>Licensed TIV</title>
            <description>Subjects received one dose of non-adjuvanted trivalent subunit influenza vaccine (TIV).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Ratio (GMR) of Post- Versus Pre-vaccination HI Titers, Against Heterologous Strains</title>
          <description>The GMR of post-vaccination versus pre-vaccination HI titers (day 22/day 1) in overall group and in subjects with pre-defined co-morbidities (high risk group), against heterologous strains, three weeks after vaccination with aTIV or TIV.</description>
          <population>Analysis was done on the FAS.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="887"/>
                <count group_id="O2" value="881"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H3N2/Brisbane strain (N=887,880), overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.76" lower_limit="5.02" upper_limit="6.6"/>
                    <measurement group_id="O2" value="3.87" lower_limit="3.37" upper_limit="4.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2/Wisconsin strain, overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.95" lower_limit="4.36" upper_limit="5.62"/>
                    <measurement group_id="O2" value="3.54" lower_limit="3.12" upper_limit="4.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain (N=887,880), overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.76" lower_limit="5.2" upper_limit="6.38"/>
                    <measurement group_id="O2" value="5.28" lower_limit="4.76" upper_limit="5.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2/Brisbane strain (N=330,333), high risk group</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.42" lower_limit="4.47" upper_limit="6.57"/>
                    <measurement group_id="O2" value="4.15" lower_limit="3.43" upper_limit="5.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2/Wisconsin strain (N=330,333), high risk group</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.67" lower_limit="3.87" upper_limit="5.62"/>
                    <measurement group_id="O2" value="3.73" lower_limit="3.1" upper_limit="4.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain (N=330,333), high risk group</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.41" lower_limit="4.66" upper_limit="6.28"/>
                    <measurement group_id="O2" value="4.77" lower_limit="4.11" upper_limit="5.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Achieving Seroconversion in HI Titers, Against Heterologous Strains</title>
        <description>The percentage of subjects achieving seroconversion in HI titers from baseline, in overall group and in subjects with pre-defined co-morbidities (high risk group), against heterologous strains, three weeks after vaccination with aTIV or TIV.
Seroconversion is defined as prevaccination HI titer &lt;10 and postvaccination HI titer ≥40 or at least a 4-fold increase in HI titers from prevaccination HI titer ≥10.</description>
        <time_frame>Day 22 post vaccination</time_frame>
        <population>Analysis was done on the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>aTIV (Pooled)</title>
            <description>Subjects received one dose of MF59-adjuvanted trivalent subunit influenza vaccine (aTIV) from one of three consecutive lots (Lot 1, Lot 2 or Lot 3).</description>
          </group>
          <group group_id="O2">
            <title>Licensed TIV</title>
            <description>Subjects received one dose of non-adjuvanted trivalent subunit influenza vaccine (TIV).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Achieving Seroconversion in HI Titers, Against Heterologous Strains</title>
          <description>The percentage of subjects achieving seroconversion in HI titers from baseline, in overall group and in subjects with pre-defined co-morbidities (high risk group), against heterologous strains, three weeks after vaccination with aTIV or TIV.
Seroconversion is defined as prevaccination HI titer &lt;10 and postvaccination HI titer ≥40 or at least a 4-fold increase in HI titers from prevaccination HI titer ≥10.</description>
          <population>Analysis was done on the FAS.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="887"/>
                <count group_id="O2" value="881"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H3N2/Brisbane, overall (N=887, 880)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.4" lower_limit="57.1" upper_limit="63.7"/>
                    <measurement group_id="O2" value="48.4" lower_limit="45.1" upper_limit="51.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2/Wisconsin, overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.5" lower_limit="54.2" upper_limit="60.8"/>
                    <measurement group_id="O2" value="45.5" lower_limit="42.2" upper_limit="48.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain, overall (N=887, 880)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.3" lower_limit="50.0" upper_limit="56.7"/>
                    <measurement group_id="O2" value="49.8" lower_limit="46.4" upper_limit="53.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2/Brisbane (N= 330,333), high risk group</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.2" lower_limit="48.7" upper_limit="59.7"/>
                    <measurement group_id="O2" value="41.4" lower_limit="36.1" upper_limit="46.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2/Wisconsin ( N= 330,333), high risk group</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.1" lower_limit="46.6" upper_limit="57.6"/>
                    <measurement group_id="O2" value="38.7" lower_limit="33.5" upper_limit="44.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain (N= 330, 333), high risk group</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.4" lower_limit="40.9" upper_limit="51.9"/>
                    <measurement group_id="O2" value="41.7" lower_limit="36.4" upper_limit="47.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of HI Antibody Responses of aTIV Versus TIV, in High Risk Group in Terms of Percentage of Subjects Achieving Seroconversion Against Homologous Strains-FAS</title>
        <description>The superiority of HI antibody responses of aTIV compared to TIV, in subjects with pre-defined co-morbidities (high risk group), assessed in terms of percentage of subjects achieving seroconversion at three weeks after vaccination against the homologous vaccine strains.
Seroconversion is defined as prevaccination HI titer &lt;10 and postvaccination HI titer ≥40 or at least a 4-fold increase in HI titers from prevaccination HI titer ≥10.</description>
        <time_frame>Day 22 postvaccination</time_frame>
        <population>Analysis was done on FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>aTIV (Pooled)</title>
            <description>Subjects received one dose of MF59-adjuvanted trivalent subunit influenza vaccine (aTIV) from one of three consecutive lots (Lot 1, Lot 2 or Lot 3).</description>
          </group>
          <group group_id="O2">
            <title>Licensed TIV</title>
            <description>Subjects received one dose of non-adjuvanted trivalent subunit influenza vaccine (TIV).</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of HI Antibody Responses of aTIV Versus TIV, in High Risk Group in Terms of Percentage of Subjects Achieving Seroconversion Against Homologous Strains-FAS</title>
          <description>The superiority of HI antibody responses of aTIV compared to TIV, in subjects with pre-defined co-morbidities (high risk group), assessed in terms of percentage of subjects achieving seroconversion at three weeks after vaccination against the homologous vaccine strains.
Seroconversion is defined as prevaccination HI titer &lt;10 and postvaccination HI titer ≥40 or at least a 4-fold increase in HI titers from prevaccination HI titer ≥10.</description>
          <population>Analysis was done on FAS.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1300"/>
                <count group_id="O2" value="1273"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 strain (N=1299,1273)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.6" lower_limit="70.1" upper_limit="75.0"/>
                    <measurement group_id="O2" value="62.0" lower_limit="59.3" upper_limit="64.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 strain (N=1299,1273)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.9" lower_limit="66.3" upper_limit="71.4"/>
                    <measurement group_id="O2" value="55.2" lower_limit="52.4" upper_limit="58.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0" lower_limit="37.3" upper_limit="42.7"/>
                    <measurement group_id="O2" value="34.3" lower_limit="31.6" upper_limit="36.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority was established if the lower bound of the 95% CI for the day 22 differences in seroconversion rates for at least 2 homologous strains was &gt;10%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Group difference (H1N1 strain)</param_type>
            <param_value>9.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.4</ci_lower_limit>
            <ci_upper_limit>13.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority was established if the lower bound of the 95% CI for the day 22 differences in seroconversion rates for at least 2 homologous strains was &gt;10%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Group difference (H3N2 strain)</param_type>
            <param_value>13.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.5</ci_lower_limit>
            <ci_upper_limit>16.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority was established if the lower bound of the 95% CI for the day 22 differences in seroconversion rates for at least 2 homologous strains was &gt;10%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Group difference (B strain)</param_type>
            <param_value>4.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.5</ci_lower_limit>
            <ci_upper_limit>8.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of aTIV Versus TIV in Terms of GMTs Against Heterologous Strains-PPS</title>
        <description>The non-inferiority of HI antibody responses of aTIV compared to TIV against the heterologous vaccine strains, in overall group and in subjects with pre-defined co-morbidities (high risk subjects), was assessed in terms of post vaccination GMTs at three weeks after vaccination .</description>
        <time_frame>Day 22 post vaccination</time_frame>
        <population>Analysis was done on PPS.</population>
        <group_list>
          <group group_id="O1">
            <title>aTIV (Pooled)</title>
            <description>Subjects received one dose of MF59-adjuvanted trivalent subunit influenza vaccine (aTIV) from one of three consecutive lots (Lot 1, Lot 2 or Lot 3).</description>
          </group>
          <group group_id="O2">
            <title>Licensed TIV</title>
            <description>Subjects received one dose of non-adjuvanted trivalent subunit influenza vaccine (TIV).</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of aTIV Versus TIV in Terms of GMTs Against Heterologous Strains-PPS</title>
          <description>The non-inferiority of HI antibody responses of aTIV compared to TIV against the heterologous vaccine strains, in overall group and in subjects with pre-defined co-morbidities (high risk subjects), was assessed in terms of post vaccination GMTs at three weeks after vaccination .</description>
          <population>Analysis was done on PPS.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="834"/>
                <count group_id="O2" value="815"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H3N2/Brisbane (overall) (N=834,814)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="369" lower_limit="329" upper_limit="414"/>
                    <measurement group_id="O2" value="255" lower_limit="227" upper_limit="287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2/Wisconsin (overall)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1037" lower_limit="940" upper_limit="1144"/>
                    <measurement group_id="O2" value="764" lower_limit="691" upper_limit="846"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain (overall) (N=834,814)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89" lower_limit="80" upper_limit="99"/>
                    <measurement group_id="O2" value="82" lower_limit="73" upper_limit="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2/Brisbane (high risk) (N=302,307)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="377" lower_limit="319" upper_limit="445"/>
                    <measurement group_id="O2" value="279" lower_limit="236" upper_limit="330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2/Wisconsin (high risk) (N=302,307)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="965" lower_limit="831" upper_limit="1121"/>
                    <measurement group_id="O2" value="751" lower_limit="646" upper_limit="873"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain (high risk) (N=302,307)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117" lower_limit="100" upper_limit="136"/>
                    <measurement group_id="O2" value="105" lower_limit="90" upper_limit="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of the 95% CI for the day 22 vaccine group GMT ratios for all 3 heterologous strains was &gt;0.67.</non_inferiority_desc>
            <param_type>GMT Ratio (H3N2/Brisbane-overall)</param_type>
            <param_value>1.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.29</ci_lower_limit>
            <ci_upper_limit>1.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of the 95% CI for the day 22 vaccine group GMT ratios for all 3 heterologous strains was &gt;0.67.</non_inferiority_desc>
            <param_type>GMT Ratio (H3N2/Wisconsin-overall)</param_type>
            <param_value>1.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.23</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of the 95% CI for the day 22 vaccine group GMT ratios for all 3 heterologous strains was ≥0.67.</non_inferiority_desc>
            <param_type>GMT Ratio (B strain-overall)</param_type>
            <param_value>1.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of the 95% CI for the day 22 vaccine group GMT ratios for all 3 heterologous strains was &gt;0.67.</non_inferiority_desc>
            <param_type>GMT Ratio(H3N2/Brisbane-high risk group)</param_type>
            <param_value>1.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.13</ci_lower_limit>
            <ci_upper_limit>1.61</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of the 95% CI for the day 22 vaccine group GMT ratios for all 3 heterologous strains was &gt;0.67.</non_inferiority_desc>
            <param_type>GMT Ratio(H3N2/Wisconsin-high risk group</param_type>
            <param_value>1.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.1</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of the 95% CI for the day 22 vaccine group GMT ratios for all 3 heterologous strains was &gt;0.67.</non_inferiority_desc>
            <param_type>GMT Ratio (B strain-high risk group)</param_type>
            <param_value>1.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of aTIV Versus TIV in Terms of GMTs Against Heterologous Strains-FAS</title>
        <description>The superiority of HI antibody responses of aTIV compared to TIV against the heterologous vaccine strains, in overall group and in subjects with pre-defined co-morbidities (high risk subjects), was assessed in terms of post vaccination GMTs at three weeks after vaccination.</description>
        <time_frame>Day 22 post vaccination</time_frame>
        <population>Analysis was done on FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>aTIV (Pooled)</title>
            <description>Subjects received one dose of MF59-adjuvanted trivalent subunit influenza vaccine (aTIV) from one of three consecutive lots (Lot 1, Lot 2 or Lot 3).</description>
          </group>
          <group group_id="O2">
            <title>Licensed TIV</title>
            <description>Subjects received one dose of non-adjuvanted trivalent subunit influenza vaccine (TIV).</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of aTIV Versus TIV in Terms of GMTs Against Heterologous Strains-FAS</title>
          <description>The superiority of HI antibody responses of aTIV compared to TIV against the heterologous vaccine strains, in overall group and in subjects with pre-defined co-morbidities (high risk subjects), was assessed in terms of post vaccination GMTs at three weeks after vaccination.</description>
          <population>Analysis was done on FAS.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="887"/>
                <count group_id="O2" value="881"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H3N2/Brisbane (overall) (N=887,880)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="362" lower_limit="325" upper_limit="404"/>
                    <measurement group_id="O2" value="243" lower_limit="218" upper_limit="271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2/Wisconsin (overall)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1016" lower_limit="926" upper_limit="1115"/>
                    <measurement group_id="O2" value="738" lower_limit="672" upper_limit="811"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain (overall) (N=887,880)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87" lower_limit="79" upper_limit="97"/>
                    <measurement group_id="O2" value="80" lower_limit="72" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2/Brisbane (high risk) (N=302,307)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="364" lower_limit="312" upper_limit="425"/>
                    <measurement group_id="O2" value="267" lower_limit="229" upper_limit="312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2/Wisconsin (high risk) (N=302,307)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="927" lower_limit="807" upper_limit="1065"/>
                    <measurement group_id="O2" value="724" lower_limit="631" upper_limit="831"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain (high risk) (N=302,307)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112" lower_limit="97" upper_limit="129"/>
                    <measurement group_id="O2" value="99" lower_limit="87" upper_limit="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority was established if the lower bound of the 95% CI for the day 22 vaccine group GMT ratios for at least 2 heterologous strains was &gt;1.5.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT ratio (H3N2/Brisbane-overall)</param_type>
            <param_value>1.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.33</ci_lower_limit>
            <ci_upper_limit>1.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority was established if the lower bound of the 95% CI for the day 22 vaccine group GMT ratios for at least 2 heterologous strains was &gt;1.5.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT ratio(H3N2/Wisconsin-overall)</param_type>
            <param_value>1.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.25</ci_lower_limit>
            <ci_upper_limit>1.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority was established if the lower bound of the 95% CI for the day 22 vaccine group GMT ratios for at least 2 heterologous strains was &gt;1.5.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT ratio (B strain-overall)</param_type>
            <param_value>1.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority was established if the lower bound of the 95% CI for the day 22 vaccine group GMT ratios for at least 2 heterologous strains was &gt;1.5.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT ratio (H3N2/Brisbane-high risk)</param_type>
            <param_value>1.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.15</ci_lower_limit>
            <ci_upper_limit>1.61</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority was established if the lower bound of the 95% CI for the day 22 vaccine group GMT ratios for at least 2 heterologous strains was &gt;1.5.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT ratio(H3N2/Wisconsin-high risk)</param_type>
            <param_value>1.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.1</ci_lower_limit>
            <ci_upper_limit>1.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority was established if the lower bound of the 95% CI for the day 22 vaccine group GMT ratios for at least 2 heterologous strains was &gt;1.5.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT ratio (B strain-high risk)</param_type>
            <param_value>1.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of HI Antibody Responses of aTIV Versus TIV, in Terms of Percentage of Subjects Achieving Seroconversion Against Heterologous Strains-PPS</title>
        <description>The non-inferiority of HI antibody responses of aTIV compared to TIV against the heterologous strains, in overall group and in subjects with pre-defined co-morbidities (high risk group), assessed in terms of percentage of subjects achieving seroconversion at three weeks after vaccination.
Seroconversion is defined as prevaccination HI titer &lt;10 and postvaccination HI titer ≥40 or at least a 4-fold increase in HI titers from prevaccination HI titer ≥10.</description>
        <time_frame>Day 22 postvaccination</time_frame>
        <population>Analysis was done on PPS.</population>
        <group_list>
          <group group_id="O1">
            <title>aTIV (Pooled)</title>
            <description>Subjects received one dose of MF59-adjuvanted trivalent subunit influenza vaccine (aTIV) from one of three consecutive lots (Lot 1, Lot 2 or Lot 3).</description>
          </group>
          <group group_id="O2">
            <title>Licensed TIV</title>
            <description>Subjects received one dose of non-adjuvanted trivalent subunit influenza vaccine (TIV).</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of HI Antibody Responses of aTIV Versus TIV, in Terms of Percentage of Subjects Achieving Seroconversion Against Heterologous Strains-PPS</title>
          <description>The non-inferiority of HI antibody responses of aTIV compared to TIV against the heterologous strains, in overall group and in subjects with pre-defined co-morbidities (high risk group), assessed in terms of percentage of subjects achieving seroconversion at three weeks after vaccination.
Seroconversion is defined as prevaccination HI titer &lt;10 and postvaccination HI titer ≥40 or at least a 4-fold increase in HI titers from prevaccination HI titer ≥10.</description>
          <population>Analysis was done on PPS.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="834"/>
                <count group_id="O2" value="815"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H3N2/Brisbane (overall) (N=834,814)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0" lower_limit="56.5" upper_limit="63.3"/>
                    <measurement group_id="O2" value="49.1" lower_limit="45.7" upper_limit="52.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2/Wisconsin (overall)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.0" lower_limit="53.5" upper_limit="60.4"/>
                    <measurement group_id="O2" value="45.9" lower_limit="42.4" upper_limit="49.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain (overall) (N=834,814)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.8" lower_limit="49.3" upper_limit="56.2"/>
                    <measurement group_id="O2" value="49.3" lower_limit="45.8" upper_limit="52.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2/Brisbane (high risk) (N=302,307)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.3" lower_limit="48.5" upper_limit="60.0"/>
                    <measurement group_id="O2" value="41.7" lower_limit="36.1" upper_limit="47.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2/Wisconsin (high risk) (N=302,307)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.7" lower_limit="45.9" upper_limit="57.4"/>
                    <measurement group_id="O2" value="38.8" lower_limit="33.3" upper_limit="44.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain (high risk) (N=302,307)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.7" lower_limit="40.0" upper_limit="51.5"/>
                    <measurement group_id="O2" value="41.4" lower_limit="35.8" upper_limit="47.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of the 95% CI for the day 22 differences in seroconversion rates for all 3 heterologous strains was ≥-10%.</non_inferiority_desc>
            <param_type>Group difference (H3N2/Brisbane-overall)</param_type>
            <param_value>11.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.7</ci_lower_limit>
            <ci_upper_limit>15.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of the 95% CI for the day 22 differences in seroconversion rates for all 3 heterologous strains was ≥-10%.</non_inferiority_desc>
            <param_type>Group difference(H3N2/Wisconsin-overall)</param_type>
            <param_value>11.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.3</ci_lower_limit>
            <ci_upper_limit>16.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of the 95% CI for the day 22 differences in seroconversion rates for all 3 homologous strains was ≥-10%.</non_inferiority_desc>
            <param_type>Slope</param_type>
            <param_value>4.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>8.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of the 95% CI for the day 22 differences in seroconversion rates for all 3 heterologous strains was ≥-10%.</non_inferiority_desc>
            <param_type>Group difference(H3N2/Brisbane-high risk</param_type>
            <param_value>12.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.8</ci_lower_limit>
            <ci_upper_limit>19.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of the 95% CI for the day 22 differences in seroconversion rates for all 3 homologous strains was ≥-10%.</non_inferiority_desc>
            <param_type>Group difference(H3N2Wisconsin-high risk</param_type>
            <param_value>12.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.0</ci_lower_limit>
            <ci_upper_limit>20.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of the 95% CI for the day 22 differences in seroconversion rates for all 3 heterologous strains was ≥-10%.</non_inferiority_desc>
            <param_type>Group difference (B strain-high risk)</param_type>
            <param_value>4.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.1</ci_lower_limit>
            <ci_upper_limit>11.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of aTIV Versus TIV in Terms of Percentage of Subjects Achieving Seroconversion Against Heterologous Strains-FAS</title>
        <description>The superiority of HI antibody responses of aTIV compared to TIV against the heterologous vaccine strains, in overall group and in subjects with pre-defined co-morbidities (high risk subjects), was assessed in terms of percentage of subjects achieving seroconversion, at three weeks after vaccination.
Seroconversion is defined as prevaccination HI titer &lt;10 and postvaccination HI titer ≥40 or at least a 4-fold increase in HI titers from prevaccination HI titer ≥10.</description>
        <time_frame>Day 22 post vaccination</time_frame>
        <population>Analysis was done on FAS</population>
        <group_list>
          <group group_id="O1">
            <title>aTIV (Pooled)</title>
            <description>Subjects received one dose of MF59-adjuvanted trivalent subunit influenza vaccine (aTIV) from one of three consecutive lots (Lot 1, Lot 2 or Lot 3).</description>
          </group>
          <group group_id="O2">
            <title>Licensed TIV</title>
            <description>Subjects received one dose of non-adjuvanted trivalent subunit influenza vaccine (TIV).</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of aTIV Versus TIV in Terms of Percentage of Subjects Achieving Seroconversion Against Heterologous Strains-FAS</title>
          <description>The superiority of HI antibody responses of aTIV compared to TIV against the heterologous vaccine strains, in overall group and in subjects with pre-defined co-morbidities (high risk subjects), was assessed in terms of percentage of subjects achieving seroconversion, at three weeks after vaccination.
Seroconversion is defined as prevaccination HI titer &lt;10 and postvaccination HI titer ≥40 or at least a 4-fold increase in HI titers from prevaccination HI titer ≥10.</description>
          <population>Analysis was done on FAS</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="887"/>
                <count group_id="O2" value="881"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H3N2/Brisbane (overall) (N=887,880)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.4" lower_limit="57.1" upper_limit="63.7"/>
                    <measurement group_id="O2" value="48.4" lower_limit="45.1" upper_limit="51.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2/Wisconsin (overall)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.5" lower_limit="54.2" upper_limit="60.8"/>
                    <measurement group_id="O2" value="45.5" lower_limit="42.2" upper_limit="48.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain (overall) (N=887,880)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.3" lower_limit="50.0" upper_limit="56.7"/>
                    <measurement group_id="O2" value="49.8" lower_limit="46.4" upper_limit="53.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2/Brisbane (high risk) (N=330, 333)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.2" lower_limit="48.7" upper_limit="59.7"/>
                    <measurement group_id="O2" value="41.4" lower_limit="36.1" upper_limit="46.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2/Wisconsin (high risk) (N=330,333)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.1" lower_limit="46.6" upper_limit="57.6"/>
                    <measurement group_id="O2" value="38.7" lower_limit="33.5" upper_limit="44.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain (high risk) (N=330, 333)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.4" lower_limit="40.9" upper_limit="51.9"/>
                    <measurement group_id="O2" value="41.7" lower_limit="36.4" upper_limit="47.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority was established if the lower bound of the 95% CI for the day 22 differences in seroconversion rates for at least 2 heterologous strains was &gt;10%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Group difference (H3N2/Brisbane-overall)</param_type>
            <param_value>12.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.1</ci_lower_limit>
            <ci_upper_limit>16.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority was established if the lower bound of the 95% CI for the day 22 differences in seroconversion rates for at least 2 heterologous strains was &gt;10%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Group difference(H3N2/Wisconsin-overall)</param_type>
            <param_value>12.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.1</ci_lower_limit>
            <ci_upper_limit>17.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority was established if the lower bound of the 95% CI for the day 22 differences in seroconversion rates for at least 2 heterologous strains was &gt;10%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Group difference (B strain-overall)</param_type>
            <param_value>4.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.4</ci_lower_limit>
            <ci_upper_limit>8.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority was established if the lower bound of the 95% CI for the day 22 differences in seroconversion rates for at least 2 heterologous strains was &gt;10%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Group difference(H3N2/Brisbane-high risk</param_type>
            <param_value>12.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.2</ci_lower_limit>
            <ci_upper_limit>19.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority was established if the lower bound of the 95% CI for the day 22 differences in seroconversion rates for at least 2 heterologous strains was &gt;10%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Group difference(H3N2/Wisconsin-highrisk</param_type>
            <param_value>13.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.8</ci_lower_limit>
            <ci_upper_limit>20.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority was established if the lower bound of the 95% CI for the day 22 differences in seroconversion rates for at least 2 heterologous strains was &gt;10%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Group difference (B strain-high risk)</param_type>
            <param_value>5.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>11.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Persistence of GMTs Against Homologous and Heterologous Strains</title>
        <description>The GMTs against homologous and heterologous strains, persisting in subjects at six months (day 181) and one year (day 366) after vaccination with either aTIV or TIV.</description>
        <time_frame>Day 181, Day 366 post vaccination</time_frame>
        <population>The analysis was done on the FAS (persistence) subset population i.e all randomized population only from US sites who received a study vaccination, provided evaluable blood samples at day 1, day 22, day 181, and day 366.</population>
        <group_list>
          <group group_id="O1">
            <title>aTIV (Pooled)</title>
            <description>Subjects received one dose of MF59-adjuvanted trivalent subunit influenza vaccine (aTIV) from one of three consecutive lots (Lot 1, Lot 2 or Lot 3).</description>
          </group>
          <group group_id="O2">
            <title>Licensed TIV</title>
            <description>Subjects received one dose of non-adjuvanted trivalent subunit influenza vaccine (TIV).</description>
          </group>
        </group_list>
        <measure>
          <title>Persistence of GMTs Against Homologous and Heterologous Strains</title>
          <description>The GMTs against homologous and heterologous strains, persisting in subjects at six months (day 181) and one year (day 366) after vaccination with either aTIV or TIV.</description>
          <population>The analysis was done on the FAS (persistence) subset population i.e all randomized population only from US sites who received a study vaccination, provided evaluable blood samples at day 1, day 22, day 181, and day 366.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="189"/>
                <count group_id="O2" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 (homologous) Day 181</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71" lower_limit="60" upper_limit="84"/>
                    <measurement group_id="O2" value="68" lower_limit="57" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1 (homologous) Day 366</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49" lower_limit="41" upper_limit="59"/>
                    <measurement group_id="O2" value="52" lower_limit="44" upper_limit="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 (homologous) Day 181</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123" lower_limit="104" upper_limit="146"/>
                    <measurement group_id="O2" value="91" lower_limit="77" upper_limit="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 (homologous) Day 366</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70" lower_limit="59" upper_limit="84"/>
                    <measurement group_id="O2" value="54" lower_limit="45" upper_limit="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (homologous) Day 181</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" lower_limit="21" upper_limit="29"/>
                    <measurement group_id="O2" value="22" lower_limit="19" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (homologous) Day 366</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" lower_limit="18" upper_limit="24"/>
                    <measurement group_id="O2" value="20" lower_limit="17" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (heterologous) Day 181</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" lower_limit="33" upper_limit="45"/>
                    <measurement group_id="O2" value="38" lower_limit="33" upper_limit="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (heterologous) Day 366</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38" lower_limit="33" upper_limit="44"/>
                    <measurement group_id="O2" value="40" lower_limit="35" upper_limit="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2/Brisbane (heterologous) Day 181</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="84" upper_limit="120"/>
                    <measurement group_id="O2" value="81" lower_limit="68" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2/Brisbane(heterologous) Day 366</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75" lower_limit="63" upper_limit="90"/>
                    <measurement group_id="O2" value="72" lower_limit="60" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2/Wisconsin (heterologous) Day 181</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="228" lower_limit="189" upper_limit="275"/>
                    <measurement group_id="O2" value="194" lower_limit="161" upper_limit="233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2/Wisconsin (heterologous) Day 366</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190" lower_limit="157" upper_limit="231"/>
                    <measurement group_id="O2" value="182" lower_limit="150" upper_limit="221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Seroconversion Upto One Year After Vaccination, Against Homologous and Heterologous Strains</title>
        <description>The percentage of subjects demonstrating seroconversion in HI titers against homologous and heterologous strains, at six months (day 181) and one year (day 366) after vaccination with either aTIV or TIV.
Seroconversion is defined as prevaccination HI titer &lt;10 and postvaccination HI titer ≥40 or at least a 4-fold increase in HI titers from prevaccination HI titer ≥10.</description>
        <time_frame>Day 181, Day 366 post vaccination</time_frame>
        <population>The analysis was done on the FAS (persistence) subset.</population>
        <group_list>
          <group group_id="O1">
            <title>aTIV (Pooled)</title>
            <description>Subjects received one dose of MF59-adjuvanted trivalent subunit influenza vaccine (aTIV) from one of three consecutive lots (Lot 1, Lot 2 or Lot 3).</description>
          </group>
          <group group_id="O2">
            <title>Licensed TIV</title>
            <description>Subjects received one dose of non-adjuvanted trivalent subunit influenza vaccine (TIV).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Seroconversion Upto One Year After Vaccination, Against Homologous and Heterologous Strains</title>
          <description>The percentage of subjects demonstrating seroconversion in HI titers against homologous and heterologous strains, at six months (day 181) and one year (day 366) after vaccination with either aTIV or TIV.
Seroconversion is defined as prevaccination HI titer &lt;10 and postvaccination HI titer ≥40 or at least a 4-fold increase in HI titers from prevaccination HI titer ≥10.</description>
          <population>The analysis was done on the FAS (persistence) subset.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="189"/>
                <count group_id="O2" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 (homologous) Day 181</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6" lower_limit="22.3" upper_limit="35.6"/>
                    <measurement group_id="O2" value="26.2" lower_limit="20.1" upper_limit="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1 (homologous) Day 366</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5" lower_limit="13.3" upper_limit="24.8"/>
                    <measurement group_id="O2" value="19.4" lower_limit="14.0" upper_limit="25.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 (homologous) Day 181</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.0" lower_limit="29.1" upper_limit="43.3"/>
                    <measurement group_id="O2" value="24.6" lower_limit="18.7" upper_limit="31.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 (homologous) Day 366</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.9" lower_limit="11.9" upper_limit="23.1"/>
                    <measurement group_id="O2" value="12.6" lower_limit="8.2" upper_limit="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (homologous) Day 181</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" lower_limit="1.5" upper_limit="7.5"/>
                    <measurement group_id="O2" value="2.6" lower_limit="0.9" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (homologous) Day 366</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="0.6" upper_limit="5.3"/>
                    <measurement group_id="O2" value="3.1" lower_limit="1.2" upper_limit="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (heterologous) Day 181</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.65" lower_limit="0.86" upper_limit="6.07"/>
                    <measurement group_id="O2" value="3.14" lower_limit="1.16" upper_limit="6.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (heterologous) Day 366</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.23" lower_limit="1.84" upper_limit="8.17"/>
                    <measurement group_id="O2" value="3.14" lower_limit="1.16" upper_limit="6.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2/Brisbane (heterologous) Day 181</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.34" lower_limit="10.52" upper_limit="21.29"/>
                    <measurement group_id="O2" value="8.38" lower_limit="4.86" upper_limit="13.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2/Brisbane(heterologous) Day 366</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.94" lower_limit="4.51" upper_limit="12.75"/>
                    <measurement group_id="O2" value="5.24" lower_limit="2.54" upper_limit="9.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2/Wisconsin (heterologous) Day 181</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.17" lower_limit="7.87" upper_limit="17.70"/>
                    <measurement group_id="O2" value="8.90" lower_limit="5.27" upper_limit="13.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2/Wisconsin (heterologous) Day 366</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.99" lower_limit="5.33" upper_limit="14.01"/>
                    <measurement group_id="O2" value="6.28" lower_limit="3.29" upper_limit="10.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Influenza Like Illness (ILI) Across Vaccine Groups</title>
        <description>The number of subjects reporting ILI from three weeks after vaccination to up to one year in aTIV group compared to TIV group, by country.</description>
        <time_frame>Day 22 through Day 366 post vaccination</time_frame>
        <population>Analysis was done on the modified full analysis set (mFAS; effectiveness) population i.e all subjects in the randomized population who received a study vaccination but excluding those who received a non-study vaccine during the follow-up phase.</population>
        <group_list>
          <group group_id="O1">
            <title>aTIV (Pooled)</title>
            <description>Subjects received one dose of MF59-adjuvanted trivalent subunit influenza vaccine (aTIV) from one of three consecutive lots (Lot 1, Lot 2 or Lot 3).</description>
          </group>
          <group group_id="O2">
            <title>Licensed TIV</title>
            <description>Subjects received one dose of non-adjuvanted trivalent subunit influenza vaccine (TIV).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Influenza Like Illness (ILI) Across Vaccine Groups</title>
          <description>The number of subjects reporting ILI from three weeks after vaccination to up to one year in aTIV group compared to TIV group, by country.</description>
          <population>Analysis was done on the modified full analysis set (mFAS; effectiveness) population i.e all subjects in the randomized population who received a study vaccination but excluding those who received a non-study vaccine during the follow-up phase.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3497"/>
                <count group_id="O2" value="3498"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Columbia (N=516, 506)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119"/>
                    <measurement group_id="O2" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Panama (N=108, 102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Philippines (N=1836,1835)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United states (N=1037,1055)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of High Risk Subjects With Exacerbation of Preexisting Chronic Disease, Across Vaccine Groups</title>
        <description>The number of high risk subjects reporting exacerbation of preexisting chronic conditions (i.e.congestive heart failure, Chronic Obstructive Pulmonary disease (COPD), asthma, hepatic disease, renal insufficiency, and neurological/neuromuscular or metabolic disorders including diabetes mellitus) in aTIV group compared to TIV group.</description>
        <time_frame>Day 1 through Day 366 post vaccination</time_frame>
        <population>Analysis was done on the mFAS (effectiveness) population.</population>
        <group_list>
          <group group_id="O1">
            <title>aTIV (Pooled)</title>
            <description>Subjects received one dose of MF59-adjuvanted trivalent subunit influenza vaccine (aTIV) from one of three consecutive lots (Lot 1, Lot 2 or Lot 3).</description>
          </group>
          <group group_id="O2">
            <title>Licensed TIV</title>
            <description>Subjects received one dose of non-adjuvanted trivalent subunit influenza vaccine (TIV).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of High Risk Subjects With Exacerbation of Preexisting Chronic Disease, Across Vaccine Groups</title>
          <description>The number of high risk subjects reporting exacerbation of preexisting chronic conditions (i.e.congestive heart failure, Chronic Obstructive Pulmonary disease (COPD), asthma, hepatic disease, renal insufficiency, and neurological/neuromuscular or metabolic disorders including diabetes mellitus) in aTIV group compared to TIV group.</description>
          <population>Analysis was done on the mFAS (effectiveness) population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1307"/>
                <count group_id="O2" value="1281"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Healthcare Utilization Across Vaccine Groups</title>
        <description>The number of subjects with emergency room visits, unscheduled physician visits, and hospitalizations due to community acquired influenza or pneumonia, cardiopulmonary disease, cardiac disease, respiratory or pulmonary disease,in aTIV group compared to TIV group.</description>
        <time_frame>Day 1 through Day 366 post vaccination</time_frame>
        <population>Analysis was done on the mFAS (effectiveness).</population>
        <group_list>
          <group group_id="O1">
            <title>aTIV (Pooled)</title>
            <description>Subjects received one dose of MF59-adjuvanted trivalent subunit influenza vaccine (aTIV) from one of three consecutive lots (Lot 1, Lot 2 or Lot 3).</description>
          </group>
          <group group_id="O2">
            <title>Licensed TIV</title>
            <description>Subjects received one dose of non-adjuvanted trivalent subunit influenza vaccine (TIV).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Healthcare Utilization Across Vaccine Groups</title>
          <description>The number of subjects with emergency room visits, unscheduled physician visits, and hospitalizations due to community acquired influenza or pneumonia, cardiopulmonary disease, cardiac disease, respiratory or pulmonary disease,in aTIV group compared to TIV group.</description>
          <population>Analysis was done on the mFAS (effectiveness).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3499"/>
                <count group_id="O2" value="3502"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="275"/>
                    <measurement group_id="O2" value="289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Cause Mortality Rate, Across Vaccine Groups</title>
        <description>The all-cause mortality rate (excluding injury)reported in aTIV group compared to TIV group, by country.</description>
        <time_frame>Day 1 through Day 366 post vaccination</time_frame>
        <population>Analysis was done on the mFAS (effectiveness).</population>
        <group_list>
          <group group_id="O1">
            <title>aTIV (Pooled)</title>
            <description>Subjects received one dose of MF59-adjuvanted trivalent subunit influenza vaccine (aTIV) from one of three consecutive lots (Lot 1, Lot 2 or Lot 3).</description>
          </group>
          <group group_id="O2">
            <title>Licensed TIV</title>
            <description>Subjects received one dose of non-adjuvanted trivalent subunit influenza vaccine (TIV).</description>
          </group>
        </group_list>
        <measure>
          <title>All Cause Mortality Rate, Across Vaccine Groups</title>
          <description>The all-cause mortality rate (excluding injury)reported in aTIV group compared to TIV group, by country.</description>
          <population>Analysis was done on the mFAS (effectiveness).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3540"/>
                <count group_id="O2" value="3541"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Columbia (N=519, 509)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Panama (N=109, 105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Philippines (N=1873,1867)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United states (N=1039,1060)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Adverse Events Following Vaccination</title>
        <description>The number of subjects reporting solicited local and systemic adverse events and other adverse events in aTIV group compared to TIV group.</description>
        <time_frame>Day 1 through Day 7 post vaccination</time_frame>
        <population>Analysis was done on the safety set i.e all randomized subjects who received a study vaccination and provided postvaccination safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>aTIV (Pooled)</title>
            <description>Subjects received one dose of MF59-adjuvanted trivalent subunit influenza vaccine (aTIV) from one of three consecutive lots (Lot 1, Lot 2 or Lot 3).</description>
          </group>
          <group group_id="O2">
            <title>Licensed TIV</title>
            <description>Subjects received one dose of non-adjuvanted trivalent subunit influenza vaccine (TIV).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited Adverse Events Following Vaccination</title>
          <description>The number of subjects reporting solicited local and systemic adverse events and other adverse events in aTIV group compared to TIV group.</description>
          <population>Analysis was done on the safety set i.e all randomized subjects who received a study vaccination and provided postvaccination safety data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3505"/>
                <count group_id="O2" value="3495"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Local</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1137"/>
                    <measurement group_id="O2" value="593"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site erythema (N=3492, 3485)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site induration (N=3494, 3488)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site tenderness (N=3495,3483)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="739"/>
                    <measurement group_id="O2" value="391"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site swelling (N=3495,3488)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site pain (N=3495,3485)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="875"/>
                    <measurement group_id="O2" value="425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any sytemic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1120"/>
                    <measurement group_id="O2" value="902"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills (N=3495,3485)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="235"/>
                    <measurement group_id="O2" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia (N=3496,3487)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="515"/>
                    <measurement group_id="O2" value="339"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia (N=3492,3486)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="296"/>
                    <measurement group_id="O2" value="272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (N= 3495,3486)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="463"/>
                    <measurement group_id="O2" value="391"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue (N= 3494, 3484)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="466"/>
                    <measurement group_id="O2" value="361"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea (N=3492,3482)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting (N=3494,3483)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea (N=3494,3485)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168"/>
                    <measurement group_id="O2" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (≥ 38°C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122"/>
                    <measurement group_id="O2" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="210"/>
                    <measurement group_id="O2" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oral Temperature (≥ 40°C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analgesic/Antipyretic used</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158"/>
                    <measurement group_id="O2" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited adverse events (AEs) were collected from Day 1 to 7 postvaccination; unsolicited AEs from Day 1 to Day 22; Serious AEs from Day 1 to Day 366.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>aTIV (Pooled)</title>
          <description>Subjects received one dose of MF59-adjuvanted trivalent subunit influenza vaccine (aTIV) from one of three consecutive lots (Lot 1, Lot 2 or Lot 3).</description>
        </group>
        <group group_id="E2">
          <title>Licensed TIV</title>
          <description>Subjects received one dose of non-adjuvanted trivalent subunit influenza vaccine (TIV).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="264" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="243" subjects_at_risk="3537"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Idiopathic Thrombocytopenic coagulation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Sideroblastic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Dressler's syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Hypertrophic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Myocardial Ischemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Nodal arrythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Sinus Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blindness unilateral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Corneal degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Retinal neovascularisation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Viterous hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Abdominal wall hematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Erosive oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Femoral hernia,obstructive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Gastric ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Inguinal hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Pancreatic mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Peptic ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Pneumoperitonium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Volvulus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Hernia obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3537"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Chronic hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Cellulitis staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Incision site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Infectious peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Leptospirosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Meningitis aseptic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Pulmonary Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Streptococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Tetanus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Wound abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Back injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Brain herniation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Forearm Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Humerus Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Nerve injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Perirenal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Postoperative adhesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Spinal cord injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Traumatic liver injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Diabetes Mellitus</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Gouty arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Bladder adenocarcinoma stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Brain neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Breast cancer stage II</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Chronic myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stromal tumor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Lung carcinoma cell type unspecified stage IV</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Ovarian adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Pancreatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Prolymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Prostrate cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Sarcoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the cervix</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Carotid artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Cerebellar infraction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Cerebral infraction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Cervical myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Dementia alzheimer's type</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Dementia with lewy bodies</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Embolic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Guillain-barre syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Headcahe</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Hemiplegia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Ishaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Ruptured cerebral aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Stroke in evolution</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Subarachnoid hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Transient ischemic attack</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status change</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Azotemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Obstructive uropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Renal Failure acute</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3537"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Uterovaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Asthmatic crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Pulmonary edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Upper airway obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aneurysm ruptured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Peripheral artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Varicose ulceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3537"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1678" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="1257" subjects_at_risk="3537"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="186" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="172" subjects_at_risk="3537"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="258" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="176" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="480" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="379" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="292" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="255" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="1172" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="643" subjects_at_risk="3537"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="315" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="293" subjects_at_risk="3537"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="536" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="360" subjects_at_risk="3537"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="492" subjects_at_risk="3545"/>
                <counts group_id="E2" subjects_affected="426" subjects_at_risk="3537"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

